BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35118711)

  • 1. Prognostic significance of IKZF1 deletions and IKZF1
    Braun M; Pastorczak A; Sędek Ł; Taha J; Madzio J; Jatczak-Pawlik I; Wypyszczak K; Matysiak M; Derwich K; Lejman M; Kazanowska B; Szczepański T; Kowalczyk JR; Mlynarski W;
    Hematol Oncol; 2022 Aug; 40(3):430-441. PubMed ID: 35118711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IKZF1
    Stanulla M; Dagdan E; Zaliova M; Möricke A; Palmi C; Cazzaniga G; Eckert C; Te Kronnie G; Bourquin JP; Bornhauser B; Koehler R; Bartram CR; Ludwig WD; Bleckmann K; Groeneveld-Krentz S; Schewe D; Junk SV; Hinze L; Klein N; Kratz CP; Biondi A; Borkhardt A; Kulozik A; Muckenthaler MU; Basso G; Valsecchi MG; Izraeli S; Petersen BS; Franke A; Dörge P; Steinemann D; Haas OA; Panzer-Grümayer R; Cavé H; Houlston RS; Cario G; Schrappe M; Zimmermann M; ;
    J Clin Oncol; 2018 Apr; 36(12):1240-1249. PubMed ID: 29498923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1
    Liu HC; Huang YJ; Jaing TH; Wu KH; Chen SH; Wang SC; Yeh TC; Hsiao CC; Chang TK; Yen HJ; Huang FL; Lin PC; Hou JY; Sheen JM; Liao YM; Chang TY; Chen YC; Chiou SS; Yang CP; Pui CH; Liang DC; Shih LY
    Br J Haematol; 2024 Apr; 204(4):1344-1353. PubMed ID: 38479427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
    Volejnikova J; Mejstrikova E; Dörge P; Meissner B; Zimmermannova O; Svojgr K; Stanulla M; Cario G; Schrappe M; Stary J; Hrusak O; Trka J; Fronkova E
    Pediatr Blood Cancer; 2013 Mar; 60(3):420-7. PubMed ID: 22997141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.
    Olsson L; Ivanov Öfverholm I; Norén-Nyström U; Zachariadis V; Nordlund J; Sjögren H; Golovleva I; Nordgren A; Paulsson K; Heyman M; Barbany G; Johansson B
    Br J Haematol; 2015 Sep; 170(6):847-58. PubMed ID: 26018335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of IKZF1
    Kicinski M; Arfeuille C; Grardel N; Bakkus M; Caye-Eude A; Plat G; Ferster A; Uyttebroeck A; De Moerloose B; Rohrlich P; Suciu S; Bertrand Y; Cavé H
    Pediatr Blood Cancer; 2023 Jun; 70(6):e30313. PubMed ID: 36971444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The value of minimal residual disease and IKZF1 deletion for predicting prognosis in adult patients with B-cell acute lymphoblastic leukemia].
    Deng SY; Ou JW; Huang ZC; Chen JJ; Cai ZH; Liu QF; Zhou HS
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):257-263. PubMed ID: 38716597
    [No Abstract]   [Full Text] [Related]  

  • 8. Aberrant IKZF1 gene as relapse predictor in standard-risk pediatric patients with B-cell precursor acute lymphoblastic leukaemia.
    Vshyukova VS; Krasko OV; Yanchanka DA; Meleshko AN
    Int J Lab Hematol; 2022 Aug; 44(4):769-776. PubMed ID: 35505470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.
    Clappier E; Grardel N; Bakkus M; Rapion J; De Moerloose B; Kastner P; Caye A; Vivent J; Costa V; Ferster A; Lutz P; Mazingue F; Millot F; Plantaz D; Plat G; Plouvier E; Poirée M; Sirvent N; Uyttebroeck A; Yakouben K; Girard S; Dastugue N; Suciu S; Benoit Y; Bertrand Y; Cavé H;
    Leukemia; 2015 Nov; 29(11):2154-61. PubMed ID: 26050650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.
    Boer JM; van der Veer A; Rizopoulos D; Fiocco M; Sonneveld E; de Groot-Kruseman HA; Kuiper RP; Hoogerbrugge P; Horstmann M; Zaliova M; Palmi C; Trka J; Fronkova E; Emerenciano M; do Socorro Pombo-de-Oliveira M; Mlynarski W; Szczepanski T; Nebral K; Attarbaschi A; Venn N; Sutton R; Schwab CJ; Enshaei A; Vora A; Stanulla M; Schrappe M; Cazzaniga G; Conter V; Zimmermann M; Moorman AV; Pieters R; den Boer ML
    Leukemia; 2016 Jan; 30(1):32-8. PubMed ID: 26202931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
    Dörge P; Meissner B; Zimmermann M; Möricke A; Schrauder A; Bouquin JP; Schewe D; Harbott J; Teigler-Schlegel A; Ratei R; Ludwig WD; Koehler R; Bartram CR; Schrappe M; Stanulla M; Cario G
    Haematologica; 2013 Mar; 98(3):428-32. PubMed ID: 22875627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
    Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan.
    Asai D; Imamura T; Suenobu S; Saito A; Hasegawa D; Deguchi T; Hashii Y; Matsumoto K; Kawasaki H; Hori H; Iguchi A; Kosaka Y; Kato K; Horibe K; Yumura-Yagi K; Hara J; Oda M;
    Cancer Med; 2013 Jun; 2(3):412-9. PubMed ID: 23930217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20-a very high-risk subtype in B-cell acute lymphoblastic leukemia.
    Tang B; Cai Z; Wang Z; Lin D; He X; Li Q; Liang X; Huang K; Zhou X; Lin R; Xu N; Fan Z; Huang F; Sun J; Liu X; Liu Q; Zhou H
    Bone Marrow Transplant; 2022 Dec; 57(12):1751-1757. PubMed ID: 36056210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia.
    Caye A; Beldjord K; Mass-Malo K; Drunat S; Soulier J; Gandemer V; Baruchel A; Bertrand Y; Cavé H; Clappier E
    Haematologica; 2013 Apr; 98(4):597-601. PubMed ID: 23065506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IKZF1 Deletions as a Prognostic Factor in Costa Rican Patients With Pediatric B-Cell Acute Lymphoblastic Leukemia.
    Granados-Zamora M; Chaves-Herrera K; Morera-Araya E; Granados-Alfaro P; Valverde-Muñoz K; Soto-Herrera G; Santamaría-Quesada C
    J Pediatr Hematol Oncol; 2020 Aug; 42(6):e401-e406. PubMed ID: 32324698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic impact of IKZF1 deletions and UKALL genetic classifiers in paediatric B-cell precursor acute lymphoblastic leukaemia treated according to NOPHO 2008 protocols.
    Öfverholm I; Rezayee F; Heyman M; Harila A; Arvidsson L; Schmiegelow K; Norén-Nyström U; Barbany G
    Br J Haematol; 2023 Jul; 202(2):384-392. PubMed ID: 37156607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
    Michels N; Boer JM; Enshaei A; Sutton R; Heyman M; Ebert S; Fiocco M; de Groot-Kruseman HA; van der Velden VHJ; Barbany G; Escherich G; Vora A; Trahair T; Dalla-Pozza L; Pieters R; Zur Stadt U; Schmiegelow K; Moorman AV; Zwaan CM; den Boer ML
    Lancet Haematol; 2021 Oct; 8(10):e700-e710. PubMed ID: 34560013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
    Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
    Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impacts of copy number variations in B-cell differentiation and cell cycle control genes in pediatric B-cell acute lymphoblastic leukemia: a single centre experience.
    Crepinsek K; Marinsek G; Kavcic M; Prelog T; Kitanovski L; Jazbec J; Debeljak M
    Radiol Oncol; 2021 Dec; 56(1):92-101. PubMed ID: 34957727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.